CHRS vs. FENC, BDTX, STRO, MGX, ADVM, IVVD, GLUE, ELEV, CMPX, and PSTX
Should you be buying Coherus BioSciences stock or one of its competitors? The main competitors of Coherus BioSciences include Fennec Pharmaceuticals (FENC), Black Diamond Therapeutics (BDTX), Sutro Biopharma (STRO), Metagenomi (MGX), Adverum Biotechnologies (ADVM), Invivyd (IVVD), Monte Rosa Therapeutics (GLUE), Elevation Oncology (ELEV), Compass Therapeutics (CMPX), and Poseida Therapeutics (PSTX). These companies are all part of the "biological products, except diagnostic" industry.
Fennec Pharmaceuticals (NASDAQ:FENC) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends, profitability and community ranking.
In the previous week, Fennec Pharmaceuticals had 4 more articles in the media than Coherus BioSciences. MarketBeat recorded 5 mentions for Fennec Pharmaceuticals and 1 mentions for Coherus BioSciences. Coherus BioSciences' average media sentiment score of 0.28 beat Fennec Pharmaceuticals' score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.
Coherus BioSciences received 244 more outperform votes than Fennec Pharmaceuticals when rated by MarketBeat users. However, 65.29% of users gave Fennec Pharmaceuticals an outperform vote while only 64.97% of users gave Coherus BioSciences an outperform vote.
55.5% of Fennec Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are owned by institutional investors. 11.3% of Fennec Pharmaceuticals shares are owned by insiders. Comparatively, 11.0% of Coherus BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Fennec Pharmaceuticals has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
Fennec Pharmaceuticals has higher earnings, but lower revenue than Coherus BioSciences. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks.
Fennec Pharmaceuticals has a net margin of -75.50% compared to Fennec Pharmaceuticals' net margin of -92.48%.
Fennec Pharmaceuticals currently has a consensus target price of $17.33, indicating a potential upside of 89.64%. Coherus BioSciences has a consensus target price of $9.29, indicating a potential upside of 348.59%. Given Fennec Pharmaceuticals' higher probable upside, analysts clearly believe Coherus BioSciences is more favorable than Fennec Pharmaceuticals.
Summary
Fennec Pharmaceuticals beats Coherus BioSciences on 9 of the 17 factors compared between the two stocks.
Get Coherus BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coherus BioSciences Competitors List
Related Companies and Tools
